Insulin resistance and vascular wall function: Lessons from animal models

Endocrinology and Metabolism, Supplement

Volumn 4, Issue 3, 1997, Pages 155-162

  O'Brien, Sheila F ^a   Russell, James C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOSE; GLYCOSYLATED PROTEIN; INSULIN; NITRIC OXIDE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REVIEW; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0030779704     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. McVeigh GE, Brennan GM, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
2. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: association with dys-lipidaemia. Clin. Sci. 1996; 91: 567-573.
3. Williams SB, Cusco JA, Roddy M, Johnstone MT, Creager MA. Impaired nitric-oxide mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. JACC 1996; 27: 567-574.
4. Goodfellow J, Ramsey MW, Luddington LA, Jones CJH, Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 1996; 312: 744-745.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diab. Care 1993; 16: 434-444.
6. Steiner G. Hyperinsulinaemia and hypertriglyceridaemia. J. Intern. Med. 1994; 236 (Suppl 736): 23-26.
7. Laws A, Reaven G. Insulin resistance, hyperinsulinemia, dyslipidemia and cardiovascular disease. In: Braunwald E, editor. Heart Disease Update. Philadelphia, PA: WB Saunders Co. 359-367
8. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 1987; 148: 1482-1489.
9. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Nat. Acad. Sci. 1991; 88: 4651-4655.
10. Diederich D, Skopec J, Deiderich A, Dai F. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am. J. Physiol. 1994; 266: H1153-H1161.
11. Vanhoutte PM, Boulanger CM, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am. J. Cardiol. 1995; 76: 3E-12E.
12. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci. 1995; 88: 245-255.
13. Haffner SM, Miettiinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995; 44: 1386-1391.
14. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995; 75: 473-486.
15. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policeman Study population. Acta Medica Scand. (Suppl.) 1985; 701: 38-52.
16. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle aged population. Diabetologia 1980; 19: 205-210.
17. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diab. Care 1979; 2: 154-160.
18. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
19. Reaven GM, Lithell H, Landsberg L Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New Engl. J. Med. 1996; 334: 374-381.
20. Shimamoto K, et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23 (Suppl. I): I29-I33.
21. Shimamoto K, Ura N, Nakagawa M, Higashiura K, Takizawa H, Miyazaki Y, Nomura N, Hirata A, Takagawa Y, Murakami H, Iimura O. The mechanisms of improvement of insulin sensitivity by angiotensin converting enzyme inhibitor. Clin. Exper. Hypertens. 1996; 18: 257-266.
22. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann. Int. Med. 1996; 125: 221-232.
23. Despres JP. Abdominal obesity and the risk of coronary artery disease. Can. J. Cardiol. 1992; 8: 561-562.
24. Rosenthal M, Haskell WL, Solomon R, Widstrom, A, Reaven GM. Demonstration of a relationship between level of physical training and insulin stimulated glucose utilization in normal humans. Diabetes 1983; 32: 408-411.
25. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diab. Care 1992; 15: 773-781.
26. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
27. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-142.
28. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989; 83: 1774-1777.
29. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann. Int. Med. 1994; 120: 227-237.
30. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br. J. Pharmacol. 1988; 93: 515-524.
31. Russell JC. The atherosclerosis-prone JCR:LA-corpulent rat. In: Woodford FP, Davignon J, Sniderman A, editors. Atherosclerosis X: Proceedings of the 10th International Symposium on Atherosclerosis. International Congress Series No. 1066. Amsterdam, The Netherlands: Elsevier Science 1995; 121-125.
32. Wexler BC. Spontaneous arteriosclerosis in repeatedly bred male and female rats. J. Atheroscler. Res. 1964; 4: 57-80.
33. Wexler BC, lams SG, Judd JT. Arterial lesions in repeatedly bred spontaneously hypertensive rats. Circ. Res. 1976; 38: 494-501.
34. Wexler BC, Greenberg BP. Effect of gonadectomy on isoproterenol-induced myocardial infarction. Angiology 1979; 30: 377-394.
35. Peric-Golia L, Peric-Golia M. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis 1983; 46: 57-65.
36. Tanaka T, Tsuchihashi Y, Katsume H, Ijichi H, Ibata Y. Comparison of cardiac lesions induced in rats by isoproterenol and by repeated stress of restraint and water immersion with special reference to etiology of cardiomyopathy. Jap. Circ. J. 1980; 44: 971-982.
37. Tanaka T. Electron microscopic study of cardiac lesions induced in rats by isoproterenol and by repeated stress. Jap. Circ. J. 1981; 45: 1342-1354.
38. Russell JC, Ahuja SK, Manickavel V, Rajotte RV, Amy RM. Insulin resistance and impaired glucose tolerance in the atherosclerosis-prone LA/N corpulent rat. Arteriosclerosis 1987; 7: 620-626.
39. Ahuja SK, Manickavel V, Amy RM, Russell JC. Age-related qualitative and quantitative changes in the endocrine pan-cras of the LA/N-corpulent rat. Diab Res. 1987; 6: 137-144.
40. Dolphin PJ, Stewart B, Amy RM, Russell JC. Serum lipids and lipoproteins in the atherosclerosis prone LA/N-corpulent rat. Biochim. Biophys. Acta 1987; 919: 140-148.
41. Russell JC, Graham S, Hameed M. Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism 1994; 43: 538-543.
42. Russell JC, Koeslag DG, Amy RM, Dolphin PJ. Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis 1989; 869-876.
43. Zucker LM, Zucker TF. Fatty: a new mutation in the rat. J. Hered. 1961; 52: 275-278.
44. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat, 'fatty.' Endocrinology 1972; 90: 1320-1330.
45. Yen TT, Shaw WN, Yu PC. Genetics of obesity in Zucker rats and Koletsky rats. Heredity 1977; 38: 373-376.
46. McCune SA, Chu Y, Jurin RR, Peterson RG. Comparison of the obese and lean rats from the mating of heterozygote SHHF/Mcc-cp and ZDF/Drt-fa rats. Int. J. Obes. 1991; 15(Suppl. 3): 17.
47. Chua SC, Chung WK, Wupeng et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the ob (leptin) receptor. Science 1996; 271: 994-996.
48. Phillips MS, Liu QY, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nature Genetics. 1996; 13: 18-19.
49. Pederson RA, Campos RV, Buchan AMJ, Chisholm CB, Russell JC, Brown JC. Comparison of the enteroinsular axis in two strains of obese rats: the fatty Zucker and JCR: LA-corpulent. Int. J. Obes. 1991; 15: 461-470.
50. Amy RM, Dolphin PJ, Pederson RA, Russell JC. Atherogenesis in two strains of obese rats. The fatty Zucker and LA/N-corpulent. Atherosclerosis 1988; 69: 199-209.
51. Chan CB, McPhail RM, Kibenge MT, Russell JC. Increased glucose phosphorylation activity correlates with insulin secretory capacity of male JCR:LA-corpulent rat islets. Can. J. Physiol. Pharmacol. 1995; 73: 501-508.
52. Vydelingum S, Shillabeer G, Hatch G, Russell JC, Lau DCW. Overexpression of the obese gene in the genetically obese JCR:LA-corpulent rat. Biochem. Biophys. Res. Commun. 1995; 216: 148-153.
53. Williams G, Shellard L, Lewis DA, McKibbin PE, McCarthy HD, Koeslag DG, Russell JC. Hypothalamic neuropeptide Y disturbances in the obese cp/cp JCR:LA-corpulent rat. Peptides 1992; 13: 537-540.
54. Lewis DA, Shellard LB, Koeslag DG, Boer DP, McCarthy HD, McKibbin PE, Russell JC, Williams G. Intense physical exercise increases regional hypothalamic neuropeptide Y concentrations in rats: close similarity to changes induced by food restriction. Am. J. Physiol. 1993; 264: E279-E284.
55. Russell JC, Graham SE, Dolphin PJ, Brindley DN. Sex differences in the effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Can. J. Physiol. Pharmacol. 1996; 74: 879-886.
56. Vance JE, Russell JC. Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J. Lipid. Res. 1990; 31: 1491-1501.
57. Russell JC, Amy RM. Early atherosclerotic lesions in a susceptible rat model: the LA/N-corpulent rat. Atherosclerosis 1986; 60: 119-129.
58. Russell JC, Amy RM. Myocardial and vascular lesions in the LA/N-corpulent rat. Can. J. Physiol. Pharmacol. 1986; 64: 1272-1280.
59. Russell JC, Amy RM, Graham S, Wenzel LM, Dolphin PJ. Effect of castration on hyperlipidemic, insulin resistant JCR:LA-corpulent rats. Atherosclerosis 1993; 100: 113-122.
60. Steiner G. Hypertriglyceridemia and carbohydrate intolerance: interrelations and therapeutic implications. Am. J. Cardiol. 1986; 57(Suppl.): 27G-30G.
61. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34: 7-12.
62. Russell JC, Koeslag DG, Dolphin PJ, Amy RM. Beneficial effects of acarbose in the atherosclerosis-prone JCR:LA-corpulent rat. Metabolism 1993; 42: 218-223.
63. Russell JC, Amy RM, Graham SE, Dolphin PJ, Wood GO, Bar-Tana J. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β′-tetramethylhexa-decanedioic acid (MEDICA 16). Arterioscler. Thromb. Vasc. Biol. 1995; 15: 918-923.
64. Russell JC, Amy RM, Manickavel V, Dolphin PJ. Effects of chronic ethanol consumption in atherosclerosis-prone JCR:LA-corpulent rat. Arteriosclerosis 1989; 9: 122-128.
65. Russell JC, Amy RM, Manickavel V, Dolphin PJ, Epling WF, Pierce D, Boer DP. Prevention of myocardial disease in JCR:LA-corpulent rats by running. J. Appl. Physiol. 1989; 66: 1649-1655.
66. Russell JC, Amy RM, Koeslag DG, Dolphin PJ. Independence of myocardial disease in the JCR:LA-corpulent rat of plasma cholesterol concentration. Clin. Invest. Med. 1991; 14: 288-295.
67. Russell JC, Amy RM, Dolphin PJ. Effect of dietary n-3 fatty acids on atherosclerosis prone JCR:LA-corpulent rats. Exp. Mol. Pathol. 1991; 55: 285-293.
68. McNamee CJ, Kappagoda CT, Kunjara R, Russell JC. Defective endothelium-dependent relaxation in the JCR:LA-corpulent rat. Circ. Res. 1994; 74: 1126-1132.
69. Absher PM, Schneider DJ, Russell JC, Sobel BE. Increased proliferation of explanted vascular smooth cells: A marker presaging atherosclerosis. Atherosclerosis, in press.
70. Lopaschuck GD, Russell JC. Myocardial function and energy substrate metabolism in the insulin resistant JCR:LAcorpulent rat. J. Appl. Physiol. 1991; 71: 1302-1308.
71. Richardson M, Kurowski EM, Carrol KK. Early lesion development in the aortas of rabbits fed low-fat cholesterol-free, semipurified casein diet. Atherosclerosis 1994; 107: 165-178.
72. Richardson M, Hadcock SJ, DeReske M, Cybulsky MI. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler. Thromb. 1994; 14: 760-764.
73. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br. J. Haematol. 1995; 92: 747-750.
74. Lucore CL, Fujii S, Wan T-C, Sobel BE, Billadello JJ. Regulation of expression of type 1 plasminogen activator inhibitor in hep G2 cells by epidermal growth factor. J. Biol. Chem. 1988; 263: 15845-15848.
75. Fujii S, Lucore CL, Hoskins WE, Billadello JJ, Sobel BE. Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications. Am. J. Cardiol. 1989; 63: 1505-1511.
76. Padró T, Emeis JJ, Steins M, Schmid KW, Keina J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler. Thromb. Vase. Biol. 1995; 15: 893-902.
77. Kohn RA, Cerami A, Monnier VM. Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 1984; 33: 57-59.
78. Esposito C, Gerlach H, Grett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of surface coagulant properties. J. Exp. Med. 1989; 170: 1387-1407.
79. Cozzolino F, Torcia G, Ziche M, Ogawa S, Brett J, Koga S, Vlassara H, Nawroth P, Stern D. Advanced glycosylation end products (AGEs) stimulate endothelial cells (EC) growth in vitro and in vivo. Circulation 1990; 82(Suppl. III): 142.
80. Vlassara H, Brownlee M, Monogue KR, Dinarelto CA, Pasegian A. Cachectin, TNF and IL-1 induced by glucose-modified protein: role in normal tissue remodeling. Science 1988; 240: 1546-1548.
81. Vlassara H, Brownlea M, Cerami A. High affinity receptor mediated uptake and degradation of glucose modified proteins. Proc. Natl. Acad. Sci. USA 1985; 82: 5588-5592.
82. Kirsten M, et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet derived growth factor. Role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA 1990; 87: 9010-9014.
83. Neeper M, Schmidt AM, Brett J, Van SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992; 267: 14998-15004.
84. Schmidt AM, Hori O, Brett J, Van SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 1994; 14: 1521-1528.
85. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. USA. 1994; 91: 8807-8811.
86. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 1994; 91: 7742-7746.
87. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 1995; 96: 1395-1403.